Vitamin U, S-methylmethionine supplement
500 mg per capsule, 60 capsules. One active ingredient, third-party tested.
$49
Shop now
S-methylmethionine (Vitamin U) has been studied in human clinical trials since 1949. This page compiles every published study we have located – human trials, reviews, and animal studies – organized by topic so you can find what's relevant to you.
Vitamin U is not a new or fringe compound. It has been an approved prescription medicine in Japan since 1960 and is sold in Ukrainian pharmacies as the dietary supplement Doctovit, and the research base spans more than 70 years, multiple countries, and many independent research groups. What you will not find is a single study claiming it cures anything. What you will find is a consistent pattern: improved mucosal healing, reduced symptoms, and a safety profile that has raised no serious concerns at studied doses.
This database is updated as new research is published. If you find a study missing from this list, email us at hello@vitaminyou.shop.
What the research covers: quick summary
- Earliest human trial: 1949 (Cheney, Stanford)
- Gastritis and ulcer studies: 10+ human trials and clinical reviews
- Regulatory status: Prescription medicine in Japan since 1960; sold as a supplement in Ukraine and the US
- Dose range studied in human trials: 200 mg/day to 2,000 mg/day
- Safety: No serious adverse effects reported in any published study at studied doses
- Most recent review: 2026 (Ananian et al., critical assessment of the evidence)
Section 1: Gastritis and peptic ulcer – human studies
These are the clinical trials most directly relevant to people living with chronic gastritis or peptic ulcers. They span 1949 to 2023.
Rapid Healing of Peptic Ulcers in Patients Receiving Fresh Cabbage Juice (1949) – Cheney G
What they studied: 13 patients with peptic ulcers (6 gastric, 7 duodenal) drank fresh cabbage juice, the food Cheney found richest in the anti-ulcer factor he called Vitamin U. Healing was checked by X-ray and gastroscopy.
What they found: Average ulcer crater healing time was 7.3 days for the gastric ulcers and 10.4 days for the duodenal ulcers. Cheney compared these with averages reported in the medical literature for standard treatment: 42 days and 37 days. There was no concurrent control group.
Why it matters: This is the original human evidence behind Vitamin U, and the paper in which Cheney first used the name. The 7-day vs. 42-day figure is the one most often cited by later researchers, but it compares 6 patients with published averages, not with a control group.
The Nature of the Anti-Peptic Ulcer Dietary Factor (1950) – Cheney G
What they studied: Cheney's account of his work on the anti-ulcer factor in raw cabbage and other vegetables, drawing on both human observations and guinea pig experiments.
What they found: The factor protected guinea pigs against histamine-induced gastric ulcers, consistent with his human results.
Why it matters: Cheney had not yet identified the chemical. S-methylmethionine was isolated and identified as the compound by McRorie and colleagues in 1954. This paper documents the factor before it had a chemical name.
Anti-Peptic Ulcer Dietary Factor (Vitamin “U”) in the Treatment of Peptic Ulcer (1950) – Cheney G
What they studied: Cheney's report to dietitians on using Vitamin U-rich foods, mainly raw cabbage juice, in the dietary treatment of peptic ulcer patients.
What they found: Cheney reported faster ulcer healing with the cabbage juice diet, in line with his 1949 trial. The paper has no abstract online, so we describe it from its title and Cheney's other work.
Why it matters: It brought Vitamin U to dietitians, the people who planned ulcer diets at the time.
Vitamin U Therapy of Peptic Ulcer (1952) – Cheney G
What they studied: 100 patients with peptic ulcer given raw cabbage juice.
What they found: Rapid relief of pain, and ulcer crater healing times (checked by X-ray) much shorter than those reported in the literature for standard diet and drug therapy.
Why it matters: A far larger group than the 1949 trial, with the same result. It still compared against published averages rather than a control group, which is why the San Quentin trial that followed matters.
Vitamin U Therapy of Peptic Ulcer; Experience at San Quentin Prison (1956) – Cheney G, Waxler S, Miller I
What they studied: A double-blind, placebo-controlled trial in inmates with a diagnosed peptic ulcer crater. Patients received either concentrated cabbage juice or a look-alike placebo, and healing was checked by repeated X-rays over 22 days.
What they found: The authors concluded that concentrated cabbage juice was effective in healing peptic ulcers, based on X-ray imaging rather than self-reported symptoms.
Why it matters: The first placebo-controlled trial of Vitamin U. Symptom improvement can be placebo; visible healing on imaging in a blinded trial is harder to dismiss.
The Effect of Vitamin U on the Course of Gastric Ulcer and Duodenal Ulcer (1972) – Starkova IV, Zhirnov VYa
What they studied: A Soviet controlled study in 47 patients with gastric or duodenal ulcer. 32 received 200 mg/day of Vitamin U for 30 days alongside a standard ulcer diet; 15 controls received standard drug therapy.
What they found: The ulcer crater disappeared on X-ray in 29 of the 32 Vitamin U patients by day 30, compared with 40% of controls. Most treated patients were free of symptoms by week 3.
Why it matters: An early Soviet study with a control group, and the lowest dose used in any trial on this page. It is part of a long line of Soviet and post-Soviet clinical research that treated Vitamin U as a standard medical tool.
Results of a Clinical Trial of Vitamin U in Peptic Ulcer and Chronic Gastritis (1973) – Mansurov HH, Pinhasov II
Cited in Astapovskiy et al. review, Vrach (2022)
What they studied: A USSR clinical trial testing Vitamin U in patients with peptic ulcer disease and in patients with chronic gastritis.
What they found: The original paper is not available online, so we cannot report its numbers. It is cited in the 2022 review by Astapovskiy, Zhukova, Drozdov and Shikh.
Why it matters: One of the earliest studies to include chronic gastritis patients, which makes it directly relevant to people with gastritis who do not have confirmed ulcers.
Doctovit (Vitamin U with B5) in H. pylori-Associated Erosive and Ulcerative Lesions (2013) – Gubergrits NB, et al.
Cited in Shichkin review, Frontiers in Pharmacology (2025)
What they studied: A Ukrainian clinical study of 40 patients with H. pylori-positive erosive and ulcerative lesions of the stomach and duodenum, treated with Doctovit as part of their therapy.
What they found: We have not been able to read the original paper. Shichkin's 2025 review cites it as clinical support for combining Vitamin U with vitamin B5.
Why it matters: Doctovit is the Ukrainian Vitamin U preparation, a dietary supplement combining 100 mg of Vitamin U with 50 mg of vitamin B5. This study is part of the evidence behind its use in Ukraine.
The Use of Doctovit in the Treatment of Gastroesophageal Reflux Disease with Erosive Gastroduodenitis (2014) – Danylchenko SI, Tokarenko AI
Cited in Shichkin review, Frontiers in Pharmacology (2025)
What they studied: 60 hospitalized patients with gastroesophageal reflux disease (GERD) treated with Doctovit (Vitamin U with B5).
What they found: We have not been able to read the original paper. Shichkin's 2025 review cites it among the Ukrainian clinical studies supporting the combination.
Why it matters: Extends the evidence to reflux, which often occurs alongside erosive gastritis in real patients.
Effectiveness of Doctovit for Correction of Clinical Symptoms and Restoration of Quality of Life in Complex Therapy of Chronic Erosive H. pylori-Associated Gastritis (2019) – Gubergrits NB, Babinets LS, Halabitska IM
View on Herald of Pancreatic Club
What they studied: Patients with chronic erosive H. pylori-associated gastritis given Doctovit, 2 tablets a day after meals for 2 months, as part of their treatment.
What they found: The authors report statistically significant improvements in quality of life (SF-36 score, 4.9%) and in digestive symptom scores (GSRS, 17.2%).
Why it matters: Directly relevant to erosive gastritis, at 200 mg/day of Vitamin U.
Chronic Gastritis and Idiopathic Peptic Ulcer: Prospects for the Use of S-Methylmethionine in Complex Therapy (2018) – Drozdov VN, Shikh EV, Starodubtseva AK, Smolyarchuk EA
What they reviewed: A Russian review of S-methylmethionine as an add-on to standard treatment in chronic gastritis and idiopathic peptic ulcer (ulcers not caused by H. pylori or NSAIDs).
What they found: The authors argue that S-methylmethionine is a promising addition to standard therapy for these patients.
Why it matters: Written by the Sechenov University group that went on to run the 2023 six-month trial below. Combination therapy context: Vitamin U added to, not replacing, standard care.
Effect of 6-Month S-Methylmethionine Intake on the Quality of Life and Dyspepsia Symptoms in Patients with Chronic Gastritis (2023) – Drozdov VN, et al.
What they studied: 37 adults aged 35 to 60 with chronic gastritis took 300 mg/day of S-methylmethionine as part of a diet programme for 6 months. There was no control group.
What they found: The total digestive symptom score (GSRS) fell from 15 points at the start to 9 at 3 months and 5.5 at 6 months (p<0.05). Quality of life scores (SF-36) improved across most measures by 6 months.
Why it matters: The longest-duration human trial published in recent years, at a modest 300 mg/day. It is small and has no placebo group, so it shows what happened to these patients rather than proving the supplement caused it.
Section 2: Cytoprotection – how Vitamin U protects the stomach lining
Cytoprotection means protecting cells from damage before an injury occurs, or limiting damage once it starts. The studies here look at Vitamin U's role in supporting the stomach's mucosal barrier – the layer that shields the stomach wall from acid and irritants.
Mechanisms for Cytoprotection by Vitamin U from Ethanol-Induced Gastric Mucosal Damage in Rats (1996) – Watanabe T, et al.
What they studied: Rat model of alcohol-induced gastric mucosal injury, with Vitamin U administered before exposure.
What they found: Vitamin U protected against damage from 50% ethanol and increased the amount of mucin on the stomach surface. The protection disappeared when sulfhydryl groups were chemically blocked, pointing to a sulfhydryl-dependent mechanism.
Why it matters: Provides a mechanism for the protection: more surface mucus on the stomach lining.
Augmentative Effects on Mucin Secretion in Rabbit Gastric Mucous Cells (2000) – Watanabe T, et al.
What they studied: Cultured rabbit gastric mucous cells treated with S-methylmethionine or L-cysteine.
What they found: Vitamin U boosted mucin secretion – mucin being the gel-like substance that physically coats and protects the stomach lining.
Why it matters: The stomach's first line of defense against acid is the mucus layer. If Vitamin U increases mucin output, it may strengthen that barrier. This was shown in cells, not in people.
Effects of S-Methylmethionine on the Expression of Mucin 2 and Relevant Growth Factors in Piglet Jejunal Epithelial Cells (2022) – Yang JP, et al.
View on Indian Journal of Animal Research
What they studied: Piglet intestinal cells exposed to S-methylmethionine, measuring mucin 2 (MUC2) expression and growth factors involved in gut lining repair.
What they found: Vitamin U increased MUC2 (a key mucus protein) and the growth factors EGF, GLP-2 and IGF-1, and lowered TGF-β1.
Why it matters: Recent evidence that Vitamin U may actively support the molecular machinery that repairs gut lining cells – not just symptom relief.
Section 3: Alcohol and NSAID-induced gastric damage
NSAIDs (ibuprofen, aspirin, naproxen) and alcohol are two of the most common triggers for gastritis flares. This section covers studies specifically looking at Vitamin U's effect on that type of damage.
Sulfhydryl-Containing Agents in the Treatment of Gastric Bleeding Induced by Nonsteroidal Anti-Inflammatory Drugs (1993) – Salim AS
What they studied: A double-blind randomized controlled trial in 172 patients vomiting blood from NSAID-induced erosive gastritis. 59 received Vitamin U, 56 received cysteine, and 57 were controls.
What they found: Patients on Vitamin U (500 mg four times daily) stayed stable with no rebleeding. At 48 hours, erosions were still present in 12% of the Vitamin U group against 35% of controls. Blood transfusion was needed in 3% against 32%, and no Vitamin U patient needed emergency surgery, against 23% of controls. All differences were statistically significant.
Why it matters: This is the most methodologically rigorous study in the Vitamin U evidence base – double-blind, randomized, measuring serious clinical endpoints (transfusion and surgery).
Section 4: Safety and side effects
No serious adverse effects have been reported in any published human study of S-methylmethionine at supplementation doses. This holds across US clinical trials from the 1940s to 1950s, Soviet and Russian clinical trials from the 1970s through 2023, Ukrainian clinical studies in the 2010s, and animal toxicology studies across multiple species.
The 2026 review by Ananian et al. describes Vitamin U as low in toxicity and well tolerated, with no serious adverse effects recorded in clinical observations. Doses in human trials range from 200 mg/day to 2,000 mg/day. The VitaminYOU product provides 500 mg per capsule.
This is not medical clearance. If you are pregnant, breastfeeding, taking medications, or managing a serious condition, talk to your doctor before starting any supplement.
Section 5: Other effects – cholesterol, metabolism, and multi-organ research
Hypolipidemic Effect of L-Form S-Methylmethionine Sulfonium Chloride in Man (1981) – Nakamura N, et al.
What they studied: 26 patients with high cholesterol took 1.5 g/day for 8 weeks.
What they found: Total cholesterol fell by 9.7% and HDL cholesterol rose. Triglycerides did not change.
Why it matters: Secondary to the gastric work, but it is a human trial – not just animal data.
Sparing of Methionine Requirements: Evaluation of Human Data Takes Sulfur Amino Acids Beyond Protein (2006) – Fukagawa NK
What they studied: A US review of how much methionine and cysteine people need, and what else affects that requirement.
What they found: The review lists S-methylmethionine among the dietary sources of methyl groups that can influence methionine needs.
Why it matters: Background on where S-methylmethionine fits in sulfur amino acid metabolism. It is not a Vitamin U study as such.
Intake of S-Methylmethionine Alters Glucose Metabolism and Hepatic Gene Expression in High-Fat-Fed Mice (2025) – Egea MB, et al.
What they studied: Mice on a high-fat diet supplemented with S-methylmethionine for 10 weeks, with glucose metabolism and liver gene expression measured.
What they found: Compared with high-fat controls, mice given Vitamin U had better fasting glucose, insulin levels and insulin resistance (HOMA-IR). Liver fat and an inflammation marker did not differ.
Why it matters: Early-stage animal research on metabolic effects, extending the research picture beyond the stomach.
Section 6: Review papers – the current state of the evidence
S-Methylmethionin (Vitamin U): Experimental Studies and Clinical Perspective (2018) – Kruchinina TV, et al.
What they reviewed: The full body of Vitamin U research – experimental, clinical, and mechanistic – as of 2018.
What they found: Gastroprotective, cholesterol-lowering and antioxidant effects, drawn mostly from experimental studies, and an argument for wider clinical use.
Why it matters: A Russian academic review treating Vitamin U as an established clinical tool. Reflects how it is regarded within the Eastern European medical literature.
Gastric Cytoprotection as Basis of Gastrointestinal Mucosa Protection and Repair in Erosive Ulcerative Lesions of Various Aetiologies (2020) – Ivashkin KV, Izatullaev EA, Korneeva VR
What they reviewed: Agents that protect the lining of the digestive tract in erosive and ulcerative lesions of different causes, including methylmethionine sulfonium chloride (Vitamin U).
What they found: The authors review the efficacy and mechanism of action of these agents and include Vitamin U among those that protect and help repair the mucosa.
Why it matters: Published in the Russian Journal of Gastroenterology, Hepatology, Coloproctology, a leading specialist journal in the field.
Pharmacological Effects of S-Methylmethionine Sulfonium Chloride (Vitamin U) (2025) – Doba S, et al.
What they reviewed: Recent research on Vitamin U's protective effects across multiple organs – stomach, liver, kidneys, skin, eyes, and brain.
What they found: Antioxidant, anti-inflammatory, and gastroprotective properties reported across diverse study types.
Why it matters: Its multi-organ scope suggests the compound's mechanisms are systemic – not limited to the stomach.
Vitamin B5 and Vitamin U Review: Justification of Combined Use for the Treatment of Mucosa-Associated Gastrointestinal Pathologies (2025) – Shichkin VP
What they reviewed: Evidence for combined use of Vitamin B5 (pantothenic acid) and Vitamin U in erosive GI diseases.
What they found: Clinical evidence supports combined use, with favorable efficacy and a minimal side effect profile.
Why it matters: Validates Vitamin U's continued use in active clinical contexts in 2025, and is the research basis for a potential future VitaminYOU product.
S-Methylmethionine (Vitamin U): A Critical Narrative Review of Pharmacological Mechanisms, Evidence Levels, and Translational Barriers (2026) – Ananian AA, et al.
What they reviewed: Seventy years of Vitamin U research across every organ system studied, grading preclinical and clinical evidence separately and comparing the compound to the related methyl donor SAMe.
What they found: Gastroenterology is the one area supported by randomized human trials; most other uses rest on preclinical data only. The effects are explained by antioxidant, anti-inflammatory and regenerative activity working through glutathione maintenance and the Nrf2, ERK and NF-κB pathways. The authors call for well-designed Phase II randomized trials.
Why it matters: The most rigorous assessment of Vitamin U published to date. It also sets out why a compound with seventy years of research and a clean safety record never reached Western pharmacies: regulatory and formulation barriers, and a literature concentrated in Soviet, Eastern European and Japanese journals, not negative results.
Section 7: Clinical use in Japan and Ukraine
Vitamin U is not a frontier compound. It has been an approved prescription medicine in Japan since 1960, and in Ukraine it is sold in pharmacies as a supplement and used in clinical practice.
Japan. S-methylmethionine has been a registered prescription medicine in Japan since June 1960, sold as Cabagin U Kowa Tablets 25 mg by Kowa Company. It carries an official NHI drug price and is indicated for gastric ulcer, duodenal ulcer, gastritis, and liver function in chronic liver disease, at 25 to 75 mg three times daily. A separate over-the-counter version, Cabagin Kowa, combines a lower dose with antacids and digestive enzymes and is sold in ordinary pharmacies. The 500 mg in the VitaminYOU product reflects the higher doses used in clinical trials (Salim 1993 used 500 mg four times daily; Drozdov 2023 used 300 mg a day) rather than either Japanese dose.
Ukraine. Doctovit is sold as a dietary supplement rather than a medicine, combining Vitamin U with vitamin B5. It has been studied in published Ukrainian clinical trials (Gubergrits 2013, Danylchenko 2014, Gubergrits 2019) in patients with erosive gastroduodenal conditions, and it is used as part of combination treatment. Ukraine's clinical use reflects the broader Soviet-era medical tradition, in which Vitamin U was part of gastroenterology practice by the early 1970s.
Why this matters for the evidence question. Sixty-five years as an approved prescription medicine in a major regulated market, with no withdrawal or safety signal in that time, is a form of real-world evidence that controlled trials cannot replicate. It does not prove efficacy, and Japanese approval in 1960 reflects the evidence standards of that era rather than a modern trial programme. But it is part of the picture.
Section 8: Animal and preclinical studies
Animal studies show what a compound can do, not what it will do in humans. They are useful for understanding mechanisms. The Vitamin U animal literature consistently supports the findings from human trials.
- Cheney G (1949) – Guinea pig model. The factor in cabbage prevented histamine-induced gastric ulcers. Preclinical support for Cheney's human trials. View on PubMed
- Gessler NN, et al. (1991) – Rat studies on the metabolism of S-methylmethionine (Vitamin U) in animals, establishing how the compound is processed in vivo. View on PubMed
- Watanabe T, et al. (1996) – Rat model of ethanol-induced gastric damage. Vitamin U protected the mucosa and increased surface mucin, through a sulfhydryl-dependent mechanism. View on PubMed
- Watanabe T, et al. (2000) – Rabbit gastric cells. Vitamin U boosted mucin secretion. View on PubMed
- Ichikawa T, Ito Y, et al. (2009) – Rats given famotidine (an acid-reducing drug) made less stomach mucus. Adding S-methylmethionine sulfonium chloride prevented that loss and increased surface mucin. View on PubMed
- Lee NY, et al. (2012) – Inhibitory effect of Vitamin U on differentiation in 3T3-L1 pre-adipocyte cells, including reduced adipogenic markers and increased AMPK activity. View on PubMed
- Sokmen BB, et al. (2012) – Vitamin U reduced valproic acid-induced liver injury in rats via antioxidant and hepatoprotective mechanisms. View on PubMed
- Tunali S, Kahraman S, Yanardag R (2014) – Vitamin U, shown to be a novel free radical scavenger, prevented lens injury in rats administered with valproic acid. View on PubMed
- Sancar Baş S, et al. (2016) – Vitamin U supplementation reduced liver injury in amiodarone-administered rats. View on DergiPark
- Turkyilmaz IB, Yanardag R (2019) – Protective effect of Vitamin U against amiodarone-induced hepatic damage via antioxidative activity in rats. View on Bulgarian Chemical Communications
- Abouzed TK, et al. (2021) – Antitumor and antioxidant activity of S-methyl methionine sulfonium chloride against liver cancer induced in rats. View on PubMed
- Topaloglu D, et al. (2022) – Vitamin U protected the stomach of rats from damage caused by D-galactosamine, through antioxidant effects. View on PubMed
- Yang JP, et al. (2022) – Piglet intestinal cells. Vitamin U enhanced MUC2 mucin expression and growth factors involved in gut lining repair. View on Indian Journal of Animal Research
- Abouzed TK, et al. (2024) – Attenuative effects of zinc oxide nanoparticles and S-methylmethionine sulfonium chloride against D-galactose-induced liver oxidative stress and apoptosis in rats. View on Pakistan Journal of Zoology
- Egea MB, et al. (2025) – High-fat-fed mice. Vitamin U improved glucose regulation and altered liver gene expression. Extends evidence to metabolic effects. View on PubMed
The 2026 Ananian review describes Vitamin U as low in toxicity across the studies it assessed.
Frequently asked questions about Vitamin U research
Is there clinical evidence for Vitamin U?
Yes. Human clinical trials date to 1949. The evidence base includes trials from the United States, Japan, Iraq, the Soviet Union, Russia, and Ukraine. The most recent human trial was published in 2023 (Drozdov et al.), and the most recent review appeared in 2026 (Ananian et al.), which graded the evidence and concluded that the preclinical base is substantial while modern human trial data remains limited. The research is not extensive by modern pharmaceutical standards, but it is consistent and spans more than 70 years.
What does Vitamin U do to the stomach lining?
Based on the available research, S-methylmethionine appears to support the stomach's mucosal barrier in at least two ways: by increasing mucin secretion (the gel-like protective coating of the stomach wall) and by protecting mucosal cells from oxidative and chemical damage. The 1993 Salim double-blind RCT found no rebleeding and far fewer transfusions in patients already bleeding from NSAID-induced gastritis. The 1996 and 2000 Watanabe studies showed protective and mucin-stimulating effects in animal models.
Is Vitamin U safe to take?
No serious adverse effects have been reported in any published human study at supplementation doses. The safety profile across 70+ years of research, 65 years as a prescription medicine in Japan, and pharmacy sale in Ukraine is favorable. This does not mean it is appropriate for everyone – if you are managing a serious condition, taking medications, or pregnant, talk to your doctor first.
How long has Vitamin U been studied?
Since 1949, when Garnett Cheney at Stanford published the first human trial. That is more than 70 years of published research.
Is Vitamin U a prescription drug anywhere?
Yes, in Japan. S-methylmethionine has been an approved prescription medicine there since 1960, sold as Cabagin U Kowa Tablets 25 mg, with a lower-dose over-the-counter version also available. In Ukraine it is sold as Doctovit, which is a dietary supplement rather than a medicine. In the United States it is a supplement.
What dose of Vitamin U has been studied in humans?
Doses in published human trials range from 200 mg/day (Starkova 1972, gastric and duodenal ulcer) to 2,000 mg/day (Salim 1993, NSAID gastric bleeding). The VitaminYOU product provides 500 mg per capsule.
Does Vitamin U help with chronic gastritis specifically?
Several human studies have included chronic gastritis patients specifically (Mansurov 1973, Gubergrits 2019, Drozdov 2023). The 2023 Drozdov trial is the most recent: in 37 patients with no control group, 6 months of 300 mg/day S-methylmethionine was followed by significantly lower dyspeptic symptom scores and better quality of life. These are structure/function findings, not disease-treatment claims.
How does Vitamin U protect against NSAID damage?
The 1993 Salim double-blind RCT is the clearest evidence. In 172 patients already bleeding from NSAID-induced erosive gastritis, Vitamin U (500 mg four times daily) prevented rebleeding, cut the need for transfusion from 32% to 3%, and no patient on Vitamin U needed emergency surgery, against 23% of controls. The trial treated damage that had already happened; it did not test Vitamin U taken before NSAIDs. Animal studies suggest the mechanism is cytoprotection – supporting the mucosal barrier rather than neutralizing acid.
Related comparisons
For how S-methylmethionine's research base compares to other stomach-support compounds, see S-methylmethionine vs DGL licorice, S-methylmethionine vs zinc carnosine, and S-methylmethionine vs mastic gum, which cover the mechanism, evidence, and safety differences with each.
For a single roundup covering all five major stomach lining repair compounds side by side, see 5 stomach lining supplements compared on the evidence.
For how this research applies to specific, common questions, see Vitamin U and H. pylori, what to eat during a gastritis flare, whether it's safe to combine with a PPI, and how it actually works in the body.
Summary
The S-methylmethionine evidence base is consistent across more than 70 years, multiple countries, and multiple research approaches. Human trials in gastritis and ulcer study populations show improvements in ulcer healing times, dyspeptic symptom scores, and outcomes of NSAID-induced gastric bleeding. Mechanistic studies explain why: Vitamin U increases mucin production, protects mucosal cells from oxidative damage, and supports the repair processes in the stomach lining. Animal studies consistently confirm these mechanisms.
No serious adverse effects have been reported in any published study at studied doses.
This is not a complete picture of how Vitamin U works or in which patients it works best. The research base is real but smaller than you would find for a modern pharmaceutical drug. We represent it accurately, not selectively.
This database is for educational purposes only and does not constitute medical advice. Vitamin U supplements are not intended to diagnose, treat, cure, or prevent any disease. This statement has not been evaluated by the FDA. Consult your healthcare provider before starting any supplement.
Page last updated: September 2026. New studies added as published.
*This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.